The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 30, 2013
Filed:
Apr. 17, 2008
Shigeru Kinoshita, Osaka, JP;
Kei Tashiro, Kyoto, JP;
Masakazu Nakano, Kyoto, JP;
Tomohito Yagi, Kyoto, JP;
Kazuhiko Mori, Kyoto, JP;
Yoko Ikeda, Kyoto, JP;
Takazumi Taniguchi, Ikoma, JP;
Masaaki Kageyama, Ikoma, JP;
Shigeru Kinoshita, Osaka, JP;
Kei Tashiro, Kyoto, JP;
Masakazu Nakano, Kyoto, JP;
Tomohito Yagi, Kyoto, JP;
Kazuhiko Mori, Kyoto, JP;
Yoko Ikeda, Kyoto, JP;
Takazumi Taniguchi, Ikoma, JP;
Masaaki Kageyama, Ikoma, JP;
Other;
Santen Pharmaceutical Co., Ltd., Osaka-shi, JP;
Abstract
A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.